Myriad(MYGN) - 2024 Q3 - Quarterly Results

Item 2.02 Results of Operations and Financial Condition Myriad Genetics reported preliminary Q3 2024 revenue of $210-$212 million, reaffirming full-year guidance of $835-$845 million despite the EndoPredict divestiture Preliminary Q3 2024 Revenue | Metric | Value (USD) | | :--- | :--- | | Preliminary Q3 2024 Revenue | $210 million - $212 million | - The preliminary Q3 2024 revenue was achieved despite the divestiture of the company's EndoPredict business in Europe, which closed on August 1, 2024[2] Reaffirmed Full-Year 2024 Revenue Guidance | Metric | Value (USD) | | :--- | :--- | | Reaffirmed Full-Year 2024 Revenue Guidance | $835 million - $845 million | - The financial guidance and data are based on preliminary, unaudited internal reports and may change upon the finalization of the company's Q3 2024 financial statements[3] Forward-Looking Statements This section outlines risks and uncertainties that could cause actual results to differ from forward-looking statements, including preliminary financial results and full-year guidance - The report contains forward-looking statements concerning the company's full-year 2024 financial guidance, expected revenue growth, and preliminary third-quarter 2024 financial results[4] - The company identifies numerous risks that could impact future performance, including but not limited to: - Decline in sales and profit margins of existing tests[4] - Increased competition and development of new competing tests[4] - Changes in governmental or private insurers' coverage and reimbursement levels[4] - Regulatory requirements or enforcement in the U.S. and foreign countries[4] - Security breaches, loss of data, and other disruptions from cyberattacks[4] - Myriad Genetics states it is not under any obligation to update or alter any forward-looking statements, except as required by law[5] Item 9.01 Financial Statements and Exhibits This section lists the exhibits filed with the Form 8-K report, specifically Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document - Exhibit 104, the Cover Page Interactive Data File (embedded within the Inline XBRL document), is filed with this report[6]